FXN and hyperinsulinemic hypoglycemia, familial, 4: In addition, these newly discovered biomarkers might also indicate if compounds such as interferon gamma-1b[30] or the antioxidant EPI-743[31] that are currently in clinical trial for FA can reverse the downstream pathomechanism of frataxin deficiency, even if they do not alter frataxin expression directly.